Sipai Health Technology Co., Ltd. (0314) AI Stock Analysis

• Market Cap: HK$2.23B
• Dividend Yield: N/A
• Average Volume (3M): 2.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: -26.21%
• EPS Growth: -29.70%
• Country: HK
• Employees: 3,236
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Plans
• EPS (TTM): -0.14
• Shares Outstanding: 765,578,100
• 10 Day Avg. Volume: 1,436,880
• 30 Day Avg. Volume: 2,048,921
• PEG Ratio: -0.37
• Price to Book (P/B): 2.67
• Price to Sales (P/S): 0.72
• P/FCF Ratio: -48.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): HK$1.92B

• Rating: 44 Neutral
• Price Target: HK$2.50 ▲(0.81% Upside)
• Action: Reiterated Date: 01/16/26
• Date: Action: Reiterated 01/16/26

The score is held down primarily by weak financial fundamentals—ongoing losses and negative operating/free cash flow. Technicals provide some offset with moderate bullish/neutral momentum, but valuation remains unattractive/unclear due to the negative P/E and lack of dividend data.

Positive Factors

Business model & product focus

Sipai's core focus on diagnostic tools and health monitoring for clinical and personal use establishes a durable product-led business model. Serving both clinical and consumer markets supports multiple adoption paths, helping sustained revenue potential as healthcare digitizes and chronic care management grows.

Balance sheet improvement

Relatively low leverage and a move to positive equity materially reduce refinancing and solvency risk over the next several quarters. This stronger capital structure supports continued R&D and commercialization investment without immediate pressure from creditors, improving strategic optionality.

Diversified revenue channels

Multiple sales channels—hospitals, providers, retail—plus partnerships, licensing and possible subscription models lower concentration risk and enhance resilience. Diversification supports more stable cash inflows and creates options to scale recurring revenue over time as solutions embed into care workflows.

Negative Factors

Persistent unprofitability

Sustained negative profitability erodes retained earnings and limits ability to self-fund growth or absorb shocks. Prolonged negative margins indicate structural cost or pricing issues that, unless resolved, will continue to impair ROE and constrain long-term reinvestment into products and market expansion.

Negative operating and free cash flow

Persistent negative operating and free cash flow forces reliance on external financing, raising dilution or interest burden risk. Weak cash conversion limits the firm’s ability to scale commercial operations, invest in R&D or weather downturns, making long-term execution more fragile.

Declining revenue trend

A steep revenue decline indicates weakening demand or competitive pressures that reduce scale benefits and pressure margins. Without a credible revenue stabilization plan, lower top-line trends will hamper recovery of profitability and cash flow, increasing strategic and operational risk over months.

Sipai Health Technology Co., Ltd. Business Overview & Revenue Model

Company Description

Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People's Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The Specialty Pharmacy Business segment operates specialty pharmacy stores; and distributes pharmaceutical products to pharmaceutical companies and other distributors. The Physician Research Assistance Business segment offers pharmaceutical companies and other clinical trial institutions site management organization services, including site feasibility, site initiation, patient recruitment, patient management, data entry and document management, on-site drug management and bio-sample management, site closure, and others; and services for image management in clinical trials. The Health Insurance Services Business segment provides insurance brokerage services to insurance companies. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

How the Company Makes Money

Sipai Health Technology Co., Ltd. generates revenue primarily through the sale of its medical devices and health management solutions. The company has established key revenue streams from direct product sales to hospitals, healthcare providers, and retail channels. Additionally, Sipai may engage in partnerships with healthcare institutions and technology firms to co-develop products or integrate its solutions into existing healthcare infrastructures. Licensing agreements for proprietary technology and potential subscription models for ongoing health monitoring services also contribute to its earnings. Furthermore, government contracts and grants for health technology innovation could serve as significant sources of revenue.

Sipai Health Technology Co., Ltd. Financial Statement Overview

Summary

Financial performance is weak: recurring losses with persistently negative net profit/EBIT/EBITDA margins and low gross margin. Operating and free cash flow remain negative, implying ongoing cash strain and reliance on external funding. Balance sheet leverage is relatively low and equity has recently improved, but negative ROE and prior equity weakness keep the score below average.

Income Statement

The company has demonstrated a mixed revenue trajectory with growth from 2019 to 2021, followed by a decline in 2024. Gross profit margin remains low, indicating limited profit from sales. There is consistent negative net profit margin due to significant losses, reflecting poor profitability and efficiency. Persistent negative EBIT and EBITDA margins indicate operational challenges and inefficiencies.

Balance Sheet

Sipai Health Technology's debt-to-equity ratio is low, indicating manageable debt levels relative to equity. However, the negative equity in earlier years signals financial instability. Recent positive equity suggests improvement, yet return on equity remains negative due to continuous net losses. The company's equity ratio has improved, enhancing balance sheet stability but still reflecting past financial distress.

Cash Flow

The company consistently reports negative operating cash flow, reflecting challenges in generating cash from operations. Free cash flow has shown improvement but remains negative, suggesting ongoing cash strain. The operating cash flow to net income ratio is unfavorable, indicating inefficiencies in converting income to cash. Financing activities have historically supported cash positions, but dependency on external funding poses risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.43B	4.57B	4.71B	4.12B	3.47B	2.70B
Gross Profit	332.69M	386.43M	412.45M	334.83M	281.06M	186.86M
EBITDA	-227.95M	-259.52M	-226.10M	-1.35B	-726.84M	-1.02B
Net Income	-317.52M	-323.74M	-255.77M	-1.37B	-3.74B	-1.04B
Balance Sheet
Total Assets	1.83B	2.27B	2.82B	2.93B	2.89B	2.48B
Cash, Cash Equivalents and Short-Term Investments	597.85M	919.77M	1.13B	1.53B	1.61B	1.67B
Total Debt	24.70M	66.49M	67.56M	67.76M	7.52B	63.59M
Total Liabilities	876.01M	1.06B	1.18B	1.10B	8.32B	4.27B
Stockholders Equity	995.88M	1.23B	1.62B	1.84B	-5.43B	-1.80B
Cash Flow
Free Cash Flow	-60.00M	-67.91M	-139.24M	-193.87M	-643.33M	-204.11M
Operating Cash Flow	-58.16M	-59.45M	-133.50M	-182.07M	-621.92M	-192.12M
Investing Cash Flow	93.73M	-622.00K	-720.81M	1.03B	-1.02B	319.62M
Financing Cash Flow	-63.31M	-184.06M	-120.55M	81.69M	559.29M	1.31B

Sipai Health Technology Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0314, the sentiment is Positive. The current price of 2.48 is above the 20-day moving average (MA) of 2.46, below the 50-day MA of 2.55, and below the 200-day MA of 3.61, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 68.66 is Neutral, neither overbought nor oversold. The STOCH value of 96.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0314.

Sipai Health Technology Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	74 Outperform	HK$6.81B	6.29	8.41%	2.76%	13.59%	6.31%
1501	70 Neutral	HK$6.48B	10.07	10.31%	―	14.06%	3.02%
1931	66 Neutral	HK$1.98B	20.84	4.85%	3.81%	0.33%	-44.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9996	48 Neutral	HK$3.82B	-14.06	-11.27%	―	29.25%	9.02%
0314	44 Neutral	HK$2.23B	-18.02	-25.47%	―	-26.21%	-29.70%
2179	44 Neutral	HK$2.00B	-2.54	-184.99%	―	―	-18.99%

Sipai Health Technology Co., Ltd. Corporate Events

Sipai Health Technology Adds Independent Director to Nomination Committee

Sipai Health Technology Co., Ltd., a Cayman Islands–incorporated company listed in Hong Kong, operates with a board structure that includes executive, non-executive and independent non-executive directors, reflecting typical governance practices for a Hong Kong–listed issuer.

The company has appointed independent non-executive director Ms. Huang Bei as a member of its nomination committee with effect from 21 December 2025, expanding the committee to four members. The change underscores a continued emphasis on independent oversight in board appointments and corporate governance, which may strengthen stakeholder confidence in the company’s governance framework.

The most recent analyst rating on (HK:0314) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Sipai Health Technology Co., Ltd. stock, see the HK:0314 Stock Forecast page.

Sipai Health Technology Outlines Board and Committee Composition

Sipai Health Technology has announced the current composition of its board of directors and the allocation of roles across four key board committees. The board is led by executive chairman Ma Xuguang alongside executive director Li Ji, non-executive director Yao Leiwen and three independent non-executive directors, who collectively chair and staff the audit, remuneration and appraisal, nomination and strategy committees. The disclosure underscores the company’s corporate governance framework, highlighting independent oversight of audit and remuneration matters and a defined distribution of responsibilities that may reassure investors about board independence and strategic supervision.

The most recent analyst rating on (HK:0314) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Sipai Health Technology Co., Ltd. stock, see the HK:0314 Stock Forecast page.

Sipai Health Formalizes Nomination Committee Governance Framework

Sipai Health Technology Co., Ltd., a Cayman Islands-incorporated company listed in Hong Kong, operates under a board structure that includes various specialized committees to oversee governance and compliance with applicable listing and regulatory standards. Its corporate governance framework emphasizes the role of independent non-executive directors in supervising key board functions.

The company has formally set out the terms of reference for its Nomination Committee, which is responsible for identifying and recommending director candidates and developing board nomination guidelines in line with laws, regulations and listing rules. The document specifies that the committee must be composed of a majority of independent non-executive directors, meet at least annually, follow defined quorum and voting rules, and keep full minutes accessible to all directors, underscoring a structured approach to board appointments and corporate governance oversight.

The most recent analyst rating on (HK:0314) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Sipai Health Technology Co., Ltd. stock, see the HK:0314 Stock Forecast page.

Sipai Health Technology Updates on Share Schemes

Sipai Health Technology Co., Ltd., a company incorporated in the Cayman Islands, has issued a supplemental announcement to its annual report for the year ended December 31, 2024. The announcement provides additional details on the company’s share schemes, including the 2017 Plan and the RSU Scheme. As of the announcement date, the outstanding options and shares under these schemes have decreased, with the 2017 Plan having approximately three years remaining and the RSU Scheme being terminated early due to all shares being vested.

The most recent analyst rating on (HK:0314) stock is a Sell with a HK$4.50 price target. To see the full list of analyst forecasts on Sipai Health Technology Co., Ltd. stock, see the HK:0314 Stock Forecast page.